Spinal muscular atrophy

被引:676
作者
Lunn, Mitchell R. [2 ]
Wang, Ching H. [1 ]
机构
[1] Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Div Pediat Neurol, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
关键词
D O I
10.1016/S0140-6736(08)60921-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation. Although no medical treatment is available, investigations have elucidated possible mechanisms underlying the molecular pathogenesis of the disease. Treatment strategies have been developed to use the unique genomic structure of the SMN1 gene region. Several candidate treatment agents have been identified and are in various stages of development. These and other advances in medical technology have changed the standard of care for patients with spinal muscular atrophy. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, therapeutic development, and evidence from clinical trials.
引用
收藏
页码:2120 / 2133
页数:14
相关论文
共 159 条
[1]   Phenylbutyrate increases SMN expression in vitro:: relevance for treatment of spinal muscular atrophy [J].
Andreassi, C ;
Angelozzi, C ;
Tiziano, FD ;
Vitali, T ;
De Vincenzi, E ;
Boninsegna, A ;
Villanova, M ;
Bertini, E ;
Pini, A ;
Neri, G ;
Brahe, C .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2004, 12 (01) :59-65
[2]   Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients [J].
Andreassi, C ;
Jarecki, J ;
Zhou, JH ;
Coovert, DD ;
Monani, UR ;
Chen, XC ;
Whitney, M ;
Pollok, B ;
Zhang, ML ;
Androphy, E ;
Burghes, AHM .
HUMAN MOLECULAR GENETICS, 2001, 10 (24) :2841-2849
[3]   Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells [J].
Angelozzi, C. ;
Borgo, F. ;
Tiziano, F. D. ;
Martella, A. ;
Neri, G. ;
Brahe, C. .
JOURNAL OF MEDICAL GENETICS, 2008, 45 (01) :29-31
[4]   Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy [J].
Avila, Amy M. ;
Burnett, Barrington G. ;
Taye, Addis A. ;
Gabanella, Francesca ;
Knight, Melanie A. ;
Hartenstein, Parvana ;
Cizman, Ziga ;
Di Prospero, Nicholas A. ;
Pellizzoni, Livio ;
Fischbeck, Kenneth H. ;
Sumner, Charlotte J. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (03) :659-671
[5]   Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy [J].
Azzouz, M ;
Le, T ;
Ralph, GS ;
Walmsley, L ;
Monani, UR ;
Lee, DCP ;
Wilkes, F ;
Mitrophanous, KA ;
Kingsman, SM ;
Burghes, AHM ;
Mazarakis, ND .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (12) :1726-1731
[6]   Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system [J].
Battaglia, G ;
Princivalle, A ;
Forti, F ;
Lizier, C ;
Zeviani, M .
HUMAN MOLECULAR GENETICS, 1997, 6 (11) :1961-1971
[7]   Identification and characterization of a mouse homologue of the Spinal Muscular Atrophy-determining gene, survival motor neuron [J].
Bergin, A ;
Kim, G ;
Price, DL ;
Sisodia, SS ;
Lee, MK ;
Rabin, BA .
GENE, 1997, 204 (1-2) :47-53
[8]   Prenatal diagnosis of spinal muscular atrophy by genetic analysis of circulating fetal cells [J].
Béroud, C ;
Karliova, M ;
Bonnefont, JP ;
Benachi, A ;
Munnich, A ;
Dumez, Y ;
Lacour, B ;
Paterlini-Bréchot, P .
LANCET, 2003, 361 (9362) :1013-1014
[9]  
Bertini E, 2005, Neuromuscul Disord, V15, P802, DOI 10.1016/j.nmd.2005.07.005
[10]   An initial blueprint for myogenic differentiation [J].
Blais, A ;
Tsikitis, M ;
Acosta-Alvear, D ;
Sharan, R ;
Kluger, Y ;
Dynlacht, BD .
GENES & DEVELOPMENT, 2005, 19 (05) :553-569